Cleared Traditional

K252424 - Anti-HCV Next

K252424 is an FDA 510(k) clearance for Anti-HCV Next, manufactured by Abbott Laboratories. The device is a Class 2 Microbiology device with product code MZO cleared through the Traditional 510(k) pathway after a 270-day FDA review.

K252424 · Abbott Laboratories · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2026
Decision
270d
Days
Class 2
Risk

K252424 is an FDA 510(k) clearance for the Anti-HCV Next. Classified as Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (product code MZO), Class II - Special Controls.

Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on April 28, 2026 after a review of 270 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3169 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Abbott Laboratories devices

FDA 510(k) Submission Details - K252424

510(k) Number K252424 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 01, 2025
Decision Date April 28, 2026
Days to Decision 270 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
168d slower than avg
Panel avg: 102d · This submission: 270d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

MZO Device Classification - Class 2, Special Controls

Product Code MZO Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3169
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.